Danaher (NYSE:DHR) Stock Rating Upgraded by Wall Street Zen

Danaher (NYSE:DHR) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday, Wall Street Zen reports.

Other research analysts have also issued reports about the company. Weiss Ratings raised Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Guggenheim boosted their price objective on Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Evercore restated an “outperform” rating and set a $230.00 target price on shares of Danaher in a research report on Monday, July 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 target price on shares of Danaher in a research note on Wednesday, July 22nd. Finally, Stifel Nicolaus decreased their target price on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $235.23.

Danaher Trading Up 0.2%

DHR opened at $220.15 on Friday. Danaher has a twelve month low of $160.93 and a twelve month high of $242.80. The company has a fifty day moving average of $211.38 and a 200-day moving average of $194.66. The stock has a market cap of $154.76 billion, a PE ratio of 39.10, a price-to-earnings-growth ratio of 2.74 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.77 earnings per share. On average, sell-side analysts predict that Danaher will post 8.53 EPS for the current year.

Institutional Investors Weigh In On Danaher

Large investors have recently bought and sold shares of the stock. HF Advisory Group LLC purchased a new position in shares of Danaher in the 3rd quarter worth about $10,936,000. Armstrong Advisory Group Inc. bought a new position in Danaher during the third quarter valued at about $1,003,000. Marquette Asset Management LLC grew its position in Danaher by 192.1% during the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock valued at $25,000 after buying an additional 73 shares during the period. Schaper Benz & Wise Investment Counsel Inc. WI purchased a new stake in Danaher during the third quarter worth about $14,338,000. Finally, Argus Investors Counsel Inc. increased its holdings in Danaher by 247.1% during the third quarter. Argus Investors Counsel Inc. now owns 7,282 shares of the conglomerate’s stock worth $1,613,000 after buying an additional 5,184 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.